CMS has proposed covering tricuspid TEER for patients who present with symptomatic tricuspid regurgitation despite optimal medical therapy. The agency still has questions about the available data, however, and is seeking public comments as it makes its final decision.

As TAVR continues to grow in popularity, researchers noted, it becomes more and more important to know how different complications impact long-term outcomes.

Researchers have taken inspiration from starfish to design an AI-powered wearable device that delivers accurate real-time heart monitoring.

Boston Scientific hopes to officially launch its new IVL system in the first half of 2026.

“He has taken my freedom, my joy,” the alleged victim said. “I’m scared to go out now. I’m scared to go to my doctor’s appointments now."

Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.

Christopher M. Kramer, MD, is a longtime cardiologist and cardiac imaging specialist. His one-year term as the head of the American College of Cardiology officially began at the end of ACC.25 in Chicago.

Laxmi Mehta, MD, detailed several ways she and her colleagues at The Ohio State University are working to combat the rising levels of burnout among cardiologists.

CMS will cover TTVR for the treatment of symptomatic tricuspid regurgitation on a national level. The agency first proposed such a policy in December, taking time to consider public comments before finalizing its decision.

Researchers tracked three years of CMS data to explore how meal-based marketing may influence the habits of general and advanced heart failure cardiologists.

Is trial and error any way for a sprawling health system to roll out AI? Duke Health’s chief medical information officer believes so. 

The platform was designed to enhance the early detection of health conditions known to affect women in their 40s and older, including breast cancer, cardiovascular disease and osteoporosis.